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Abstract
Viral exacerbations of chronic obstructive pulmonary disease (COPD), commonly caused by rhinovirus (RV)
infections, are poorly controlled by current therapies. This is due to a lack of understanding of the underlying
immunopathological mechanisms. Human studies have identified a number of key immune responses that are
associated with RV-induced exacerbations including neutrophilic inflammation, expression of inflammatory cytokines
and deficiencies in innate anti-viral interferon. Animal models of COPD exacerbation are required to determine the
contribution of these responses to disease pathogenesis. We aimed to develop a short-term mouse model that
reproduced the hallmark features of RV-induced exacerbation of COPD. Evaluation of complex protocols involving
multiple dose elastase and lipopolysaccharide (LPS) administration combined with RV1B infection showed
suppression rather than enhancement of inflammatory parameters compared with control mice infected with RV1B
alone. Therefore, these approaches did not accurately model the enhanced inflammation associated with RV
infection in patients with COPD compared with healthy subjects. In contrast, a single elastase treatment followed by
RV infection led to heightened airway neutrophilic and lymphocytic inflammation, increased expression of tumour
necrosis factor (TNF)-α, C-X-C motif chemokine 10 (CXCL10)/IP-10 (interferon γ -induced protein 10) and CCL5
[chemokine (C-C motif) ligand 5]/RANTES (regulated on activation, normal T-cell expressed and secreted), mucus
hypersecretion and preliminary evidence for increased airway hyper-responsiveness compared with mice treated
with elastase or RV infection alone. In summary, we have developed a new mouse model of RV-induced COPD
exacerbation that mimics many of the inflammatory features of human disease. This model, in conjunction with
human models of disease, will provide an essential tool for studying disease mechanisms and allow testing of
novel therapies with potential to be translated into clinical practice.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is the most com-
mon chronic respiratory condition in adults and its prevalence
is expected to increase markedly in the future [1]. The clinical
course of COPD is punctuated by acute exacerbations, which are
a major cause of morbidity and mortality and place a significant
Abbreviations: AHR, airway hyper-responsiveness; BAL, bronchoalveolar lavage; CCL5, chemokine (C-C motif) ligand 5; COPD, chronic obstructive pulmonary disease; CXCL10, C-X-C
motif chemokine 10; FRC, functional residual capacity; H&E, haematoxylin and eosin; IFN, interferon; IL, interleukin; IP-10, interferon γ -induced protein 10; LPS, lipopolysaccharide;
MIP-2, macrophage inflammatory protein 2; MPO, myeloperoxidase; PAS, periodic acid–Schiff; PFA, paraformaldehyde; RANTES, regulated on activation, normal T-cell expressed and
secreted; RV, rhinovirus; TLC, total lung capacity; TNF, tumour necrosis factor.
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burden on healthcare services [2–4]. A number of different agents
have been suggested to trigger COPD exacerbations, with respir-
atory viruses [most commonly rhinoviruses (RVs)] frequently
identified [5,6].
Inflammatory responses in the airways during virus-induced
exacerbations of COPD are poorly understood. Some insight
has been gained from naturally occurring COPD exacerbation
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studies, but these studies are limited by variability in factors
such as time between virus infection and presentation and treat-
ments initiated prior to sampling. To address these issues, we
have developed a model of experimental RV-induced COPD ex-
acerbation in humans that allows sequential measurement of a
range of clinical and inflammatory parameters and has provided
a clearer understanding of the relationship between virus infec-
tion, inflammatory responses and biological and physiological
markers [7]. Key features of exacerbation in comparison with
stable-state COPD reported in this and other human studies in-
clude increased neutrophilic [7–12] and lymphocytic [7,9,11,12]
cellular airways inflammation, enhanced production of cytokines
such as tumour necrosis factor (TNF)-α [7,13], CXCL10 (C-
X-C motif chemokine 10)/IP-10 (interferon γ -induced protein
10) [14] and CCL5 [chemokine (C-C motif) ligand 5]/RANTES
(regulated on activation, normal T-cell expressed and secreted)
[9,10] in the airways, deficient type I interferon responses to RV
infection, increased virus load and enhanced airway mucus pro-
duction [7]. Additionally, RV infection in patients with COPD
has been shown to be associated with enhanced airway neutro-
philia and lymphocytosis and increased neutrophil chemokine
CXCL8/IL-8 expression compared with RV infection in healthy
smokers [7,15,16].
Animal models of chronic respiratory diseases have histor-
ically played important roles in broadening our understand-
ing of disease mechanisms, including development of the
proteinase/anti-proteinase imbalance hypothesis in COPD [17].
A mouse model of RV-induced COPD exacerbation that can
mimic what is known of human disease could therefore provide
further critical insight into diseasemechanisms and be used to test
novel therapies. However, this presents a considerable challenge
due to a limited understanding of the mechanisms driving under-
lying COPD and of the distinct clinical phenotypes in humans.
Previously described animal models of COPD have used one
of three main approaches: inhalation of noxious stimuli (most
commonly cigarette smoke), instillation of tissue-degrading pro-
teinases such as elastase or genetic manipulation [18,28,52]. Ci-
garette smoke administration models require at least 2 months’
exposure before some of the pathological features of COPD are
evident [18]. Models that use instillation of elastase produce a
rapid onset of emphysematous destruction of the lungs with mu-
cin induction and may be considered the best short-term method
for modelling severe disease. A number of studies have described
elastase-induced models of COPD with exacerbation precipit-
ated by bacteria and, more recently, RV infection [19–21]. These
models have used various protocols, including single [19,20] or
multiple [21,22] doses of intranasal elastase, differing intervals
between elastase dosing and infection [19,20,23] and the addition
of lipopolysaccharide (LPS) to model chronic bacterial coloniza-
tion [21,22]. Given this array of approaches, the optimal protocol
for recreating the features of virus-induced COPD exacerbation
that have been identified in humans is unclear.
In the present study, we describe a 10 day mouse model con-
sisting of a single dose of elastase administration to establish
severe emphysematous lung disease followed by RV infection
that recreates many of the inflammatory features of human RV-
induced COPD exacerbation.
MATERIALS AND METHODS
Animals
All studies were performed in 8–10-week-old, wild-type, female
C57BL/6 mice, purchased from Charles River Laboratories and
housed in individually ventilated cages under specific pathogen-
free conditions. During all experiments, animal welfare wasmon-
itored at least twice daily.
COPD models
Isofluorane-anaesthetizedmicewere intranasally challengedwith
1.2 units of porcine pancreatic elastase (Merck) on day 1 andwith
70 endotoxin units of LPS from Escherichia coli 026:B6 (Sigma–
Aldrich) on day 4 of the week for up to 4 consecutive weeks,
as previously described [21]. In some experiments, mice were
alternatively treated with a single dose of 1.2 units of elastase
alone. Mice treated with intranasal PBS instead of elastase or
LPS were used as controls.
RV infection
RV serotype 1B was obtained from the A.T.C.C. and propagated
inOhioHeLa cells, as described previously [24].Micewere infec-
ted intranasally under light isofluorane anaesthesiawith 2.5× 106
tissue culture infectious dose (TCID50) RV1B or UV-inactivated
RV control either 7 days after final LPS challenge in the case
of combined elastase and LPS models or 10 days after elastase
challenge in the single-dose elastase model.
Cytospin assay
Bronchoalveolar lavage (BAL) was performed as previously de-
scribed [24]. Cells were pelleted by centrifugation, resuspended
in ammonium-chloride-potassium (ACK) buffer to lyse red blood
cells, washed with PBS and resuspended in RPMI 1640 medium
with 10% FBS. Cells were then spun on to slides and stained
with Quik-Diff (Reagena) for differential counts. Counts were
performed blinded to experimental conditions.
ELISA
Cytokine and chemokine protein levels in BAL were measured
using commercial duoset ELISA kits (R&D Systems), according
to the manufacturer’s instructions.
Myeloperoxidase assay
To indirectly assess neutrophil activation, the chlorination activity
of released myeloperoxidase (MPO) was measured in BAL using
the EnzChek MPO activity assay kit (Invitrogen), according to
the manufacturer’s instructions.
Quantitative real-time PCR
Total RNAwas extracted from the excised apical lobe of the right
mouse lung using an RNeasy mini kit (Qiagen) and reverse tran-
scribed using 5 μg of random hexamers (Omniscript RT kit, Qia-
gen) as primers. Quantitative PCR was carried out using specific
primers and probes for each gene and normalized to 18S rRNA.
Primers and probes for 18S [24], RV [25], interferon β (IFN-
β) [25], interferon λ (IFN-λ) [25], MUC5AC [24] and MUC5B
[24] have been described previously. The following primer and
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probe sequenceswere used for interleukin (IL)-13 andTNF-α: IL-
13 forward 5’-GATATTGCATGGCCTCTGTAACC-3′, IL-13 re-
verse 5′-GGGCTACTTCGATTTTGGTATCG-3′, IL-13 probe 5′-
FAM-CAAGGCCCCCACTACGGTCTCCA-TAMRA;-3′ TNF-
α forward 5′-CATCTTCTCAAAATTCGAGTGACAA-3′, TNF-
α reverse 5′-TGGGAGTAGACAAGGTACAACCC-3′, TNF-α
probe 5′-FAM-CACGTCGTAGCAAAC-TAMRA-3′.
Histopathological analysis
Following BAL, lungs were perfused with PBS via the heart
and inflated with 4% paraformaldehyde (PFA), then immersion
fixed in 4% PFA for 24 h. Fixed lung samples were embedded in
paraffin wax and 5-μm-thick histological sections were cut and
stained with haematoxylin and eosin (H&E) or periodic acid–
Schiff (PAS). Mean linear intercept was determined by measur-
ing the diameter of air spaces in ten random fields per slide using
Zeiss Axiovision software v4.8.3.0. PAS staining was scored us-
ing a system described previously [26]. Ten to twenty airways
were counted per section. All counting was performed blind to
experimental conditions.
Assessment of lung function
Lung function was assessed as previously described [18]. Mice
were anaesthetized with ketamine (125 mg/kg) and xylazine
(16 mg/kg) and were then cannulated (tracheostomy with lig-
ation). Work of breathing, functional residual capacity (FRC),
total lung capacity (TLC) and dynamic lung compliance were
measured using a forced pulmonary manoeuvre system (Buxco).
An average breathing frequency of 200 breaths/minute was ap-
plied to anaesthetized animals. Each manoeuvre was performed
a minimum of three times and the average was calculated. Dy-
namic compliance readings were taken every 2 s for 2 min and the
average was calculated. The FlexiVent FX1 apparatus (SCIREQ)
was used to assess hysteresis and tissue damping. Maximal pres-
sure/volume (PV) loops were used to calculate hysteresis. For
all perturbations, a coefficient of determination of 0.95 was the
minimum allowable for an acceptable measurement. Each per-
turbation was conducted three times per animal and the average
was calculated,with aminimumventilation period of 20 s allowed
between each perturbation.
Assessment of airways hyper-responsiveness
Airway hyper-responsiveness (AHR) was measured as en-
hanced pause (PenH) in response to nebulized challenge with
methacholine, using an unrestrained whole-body plethysmo-
graphy system (Electromedsystems), as previously described
[26]. PenH is displayed as average values for a 5 min log period
post-methacholine challenge.
Statistical analyses
Mice were studied in groups of four or five and data are presented
as means+−S.E.M., representative of or comprising at least two
independent experiments. Data were analysed by ANOVA and
Bonferroni’s multiple comparison test. All statistics were calcu-
lated using Prism 4.2 software (GraPhPad).
Study approval
All animal work was completed in accordance with U.K. Home
Office guidelines (U.K. project licence PPL 70/7234).
RESULTS
Multiple doses of elastase and LPS in combination
with RV infection do not accurately model COPD
exacerbation
We initially attempted to reproduce a previously reported mouse
model of RV-induced COPD exacerbation [21] using exactly the
same dosing protocol of once weekly intranasal elastase and LPS
administration for 4 weeks followed by RV infection (Supple-
mentary Figure S1a). Consistent with the previous report of this
model, we found that induction of IFN-β and IFN-λ mRNAs in
lung tissue in vivowere reduced with 4 weeks of elastase/LPS ad-
ministration followed by RV infection (elastase/LPS + RV) com-
pared with treatment with PBS and infection with RV (PBS+RV;
modelling RV infected healthy subjects) (Figures S1b and S1c).
Lung tissue IL-13 mRNA was also increased in elastase/LPS +
RV-treated mice compared with either treatment alone (Figure
S1d), as previously reported [21].
However, in contrast with the original report of this model,
we found that elastase/LPS treatment followed by RV infec-
tion led to reduced rather than increased lung virus loads com-
pared with non-COPD mice infected with RV (Figure S1e), re-
duced rather than increased expression of TNF-α and no dif-
ference in MUC5AC mRNA levels in lung tissue compared
with PBS + RV-treated mice (Supplementary Figures S1f and
S1g). AHR was increased in mice treated with elastase/LPS
+ RV compared with PBS + RV but was reduced compared
with mice treated with elastase/LPS + UV (Supplementary
Figure S1h).
We also measured a number of other inflammatory endpoints
associated with human disease that were not originally reported
[21]. BAL neutrophil numbers on day 1 and BAL lymphocyte
numbers on day 4 post-challenge were increased with RV infec-
tion as previously shown [24] (PBS + RV compared with PBS
+ UV, Supplementary Figures S2a and S2b). BAL neutrophil
numbers were increased in elastase/LPS + RV-compared with
elastase/LPS + UV-treated mice, but were decreased compared
with PBS + RV treatment at day 1 post-challenge (Supplement-
ary Figure S2a). BAL lymphocyte numbers were no different in
elastase/LPS + RV-compared with elastase/LPS + UV-treated
mice, but were increased on day 1 post-challenge compared with
PBS + RV treatment (Supplementary Figure S2b). Levels of the
virus-inducible chemokines CXCL10/IP-10, CCL5/RANTES
andCXCL2/macrophage inflammatory protein 2 (MIP-2) inBAL
were increased by RV infection compared with uninfected con-
trols (PBS + RV compared with PBS + UV treatment), but were
not increased in elastase/LPS + RV-compared with PBS + RV-
treated mice and CXCL10/IP-10 was reduced in elastase/LPS
+ RV compared with PBS + RV administration at day 4 post-
challenge (Supplementary Figures S2c–S2e). MUC5AC protein
levels in BAL on day 4 post-challenge were increased with
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Figure 1 Single elastase/LPS treatment is sufficient to induce emphysema
Mice were challenged intranasally with elastase on day 1 and LPS on day 4 of each week or PBS as control for 1, 2, 3
or 4 weeks. At day 7, following final LPS or PBS challenge, lungs were formalin-fixed, paraffin-embedded and stained with
H&E. Representative images of mice treated with (a) PBS, (b) single dose of elastase and LPS, (c) two doses of elastase
and LPS, (d) three doses of elastase and LPS, and (e) four doses of elastase and LPS. Scale bars: 50 μm. Magnification
×100 (f) The diameter of air spaces were measured in at least ten random fields per slide and were averaged to
determine mean linear intercept. n=4 mice/group. Data were analysed by ANOVA and Bonferroni post-hoc test. *P< 0.05;
***P< 0.001.
RV infection alone (PBS + RV compared with PBS + UV;
Supplementary Figure S2f) and were also increased in elast-
ase/LPS + RV- compared with PBS + RV-treated mice on day 1
post-infection, but significantly decreased compared with elast-
ase/LPS + UV treatment at the same time point (Supplementary
Figure S2f).
Comparison of single-compared with multiple-dose
elastase and LPS to model COPD
In our hands, RV infection in the 4-week elastase/LPS COPD
model failed to produce most of the inflammatory features of
human COPD exacerbation. We speculated that inducing very
severe lung damage with multiple doses of elastase interfered
with virus infection and associated inflammatory responses, as
previously reported [19].We therefore investigated whether redu-
cing the number of doses of elastase/LPS could still induce sig-
nificant alveolar destruction with less severe lung damage. Initial
comparisons of one, two, three and four weekly doses of elastase
and LPS indicated a dose-dependent increase in emphysematous
lung changes apparent both visually in H&E-stained lung sec-
tions (Figures 1a–1e) and when quantified by measuring mean
linear intercept (Figure 1f). A single dose of elastase and LPS
was sufficient to induce emphysematous lung changes as defined
by significantly increased mean linear intercept compared with
control PBS-treated mice (Figure 1f). Despite the histological
changes induced by intranasal elastase with or without LPS ad-
ministration, none of the animals studied showed any outward
signs of illness or respiratory compromise, regardless of the dos-
ing protocol used.
To determine whether reducing elastase/LPS-induced lung
damage increased responses to infection, we compared single
with up to four doses of elastase and LPS followed by RV in-
fection. Regardless of the number of doses administered, elast-
ase/LPS failed to enhance RV-induced airway inflammation.
We observed reduced viral RNA levels in lung tissue (Fig-
ure 2a) and reduced or no difference in BAL neutrophilia,
BAL lymphocytosis (except for the four-dose protocol) and
BAL CXCL10/IP-10, CCL5/RANTES and IL-6 in elastase/LPS
+ RV-compared with PBS + RV-treated mice (Figures 2d–2f).
The number of doses of elastase and LPS therefore had little
effect on the efficacy of this model when comparing elast-
ase/LPS + RV treatment to RV infection alone. However, a
number of inflammatory endpoints including BAL neutrophilia
(one-dose elastase/LPS protocol), BAL lymphocytosis (one-
and two-dose protocols) and protein levels of CXCL10/IP-10
(one-, two- and three-dose protocols), CCL5/RANTES (one-
and two-dose protocols) and IL-6 (one-, two- and four-dose
protocols) in BAL were increased in elastase/LPS + RV-
treated mice compared with elastase/LPS + UV-treated mice
(Figures 2b–2f).
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Figure 2 Effect of differing elastase and LPS dosing protocols on RV load and RV-induced airway inflammation
Mice were challenged intranasally with elastase on day 1 and LPS on day 4 of each week or PBS as control for 1, 2, 3
or 4 weeks. At day 7 following final LPS or PBS challenge, mice were additionally challenged with RV1B or UV-inactivated
RV1B 7 days after final LPS challenge. (a) RV RNA copies in lung tissue were measured by Taqman quantitative PCR at
24 h post-infection. (b) Neutrophil numbers at 24 h post-infection and (c) lymphocyte numbers at day 4 post-infection were
enumerated in BAL by cytospin assay. (d) CCL5/RANTES, (e) CXCL10/IP-10 and (f) IL-6 proteins at 24 h post-infection
were measured in BAL by ELISA. n=5 mice/group. Data were analysed by two-way ANOVA and Bonferroni post-hoc test.
*P< 0.05; **P< 0.01; ***P< 0.001.
Single-dose elastase in combination with RV
infection more accurately models COPD
exacerbation
Alternative mouse models of COPD have successfully used
single-dose elastase administration protocols and demonstrated
enhanced inflammatory responses to bacterial challenge [19,20].
Since the combination of elastase and LPS with RV did not
produce a phenotype that we considered to be consistent with
human COPD exacerbation, regardless of the number of doses
administered, we reasoned that LPS may be activating innate im-
munity and thus directly interfering with RV infection. We there-
fore determined whether removal of the LPS component from
the protocol would lead to a more representative disease model
(Figure 3a). Similarly to combined elastase/LPS, single-dose
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Figure 3 Single-dose elastase treatment induces histological emphysema and enhances pulmonary inflammation in
RV-infected mice
(a) Mice were challenged intranasally with a single dose of elastase or PBS as control and at day 10 post-challenge, lungs
were formalin-fixed, paraffin-embedded and stained with H&E. Representative images of mice treated with (b) elastase
and (c) PBS. Scale bars: 50μm. Magnification ×100 (d). The diameter of air spaces were measured in at least ten
random fields per slide and averaged to determine mean linear intercept. On day 10 after elastase or PBS challenge,
mice were additionally challenged intranasally with RV1B or UV-inactivated RV1B (UV). (e) Neutrophil, (f) lymphocyte, (g)
macrophage and (h) total cell numbers in BAL were enumerated by cytospin assay. (i) MPO activity was measured indirectly
by assessment of chlorination of 3′ -(p-aminophenyl fluorescein) in BAL. n=5 mice/group. Data were analysed by two-way
ANOVA and Bonferroni post-hoc test. *P< 0.05; **P< 0.01; ***P< 0.001.
elastase administration to mice caused histological emphysemat-
ous lung changes compared with PBS-treated controls (Fig-
ures 3b–3d). Numbers of neutrophils (days 1 and 4 post-
challenge) and MPO activity (day 1 post-challenge) in BAL were
both significantly greater in elastase + RV-treated mice com-
pared with either elastase administration or RV infection alone
(Figures 3e and 3i). Lymphocytes in BAL were greater on day 1
post-challenge in mice treated with elastase+RV compared with
PBS + RV treatment and on day 4 post-challenge compared with
elastase + UV treatment (Figure 3f). Total cell and macrophage
numbers in BAL were increased in elastase + RV-compared with
both elastase + UV-and PBS + RV-treated mice at day 4 post-
challenge (Figures 3g and 3h).
We also observed significant increases in BAL protein levels
of CXCL10/IP-10 and CCL5/RANTES (day 1 post-challenge)
and lung tissue TNF-α mRNA expression (day 4 post-challenge)
in elastase + RV-treated mice compared with either PBS + RV
or elastase + UV treatments (Figures 4a, 4b and 4d). In addition,
BAL protein levels of CXCL2/MIP-2 were increased in elastase
+ RV-compared with elastase + UV-treated mice at day 1 post-
challenge (Figure 4c). Lung tissue gene expression of IL-13 was
significantly lower in elastase + RV- compared with PBS + RV-
treated mice (Figure 4e).
Increased mucus production and mucus plugging of the air-
ways is a recognized feature of COPD and has been shown to
be further increased by RV infection [27]. Staining of lung sec-
tions with PAS revealed abundant PAS-positivemucus-producing
cells in the airways of elastase + RV-treated mice 4 days after
RV challenge and, to a significantly lesser extent, in the air-
ways of elastase + UV-treated mice (Figures 5a, 5b and 5e). No
PAS-positive cells were visible in the airways of mice receiving
PBS in combination with either RV or UV-inactivated virus (Fig-
ures 5c, 5d and 5e). We also assessed airway mucin gene and pro-
tein levels. On day 4, after virus infection lung tissue MUC5AC
mRNA levels were increased in elastase + RV- compared with
PBS + RV- and elastase + UV-treated mice (Figure 5f). Lung
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Figure 4 Single-dose elastase treatment enhances inflammatory chemokine and cytokine production in RV-infected
mice
(a) Mice were challenged intranasally with a single dose of elastase or PBS as control. On day 10 after elastase or
PBS challenge, mice were additionally challenged intranasally with RV1B or UV-inactivated RV1B (UV). (a) CXCL10/IP-10,
(b) CCL5/RANTES and (c) CXCL2/MIP-2 proteins were measured in BAL by ELISA. (d) TNF-α and (e) IL-13 mRNA in lung
tissue was measured by Taqman quantitative PCR. n=5 mice/group. Data were analysed by two-way ANOVA and Bonferroni
post-hoc test. *P< 0.05; **P< 0.01; ***P< 0.001.
tissue MUC5AC mRNA levels were similarly increased com-
pared with PBS + RV treatment, but not compared with elastase
+UV treatment, at day 1 (Figure 5f). LungMUC5BmRNA levels
were increased at day 4 post-challenge in elastase + RV- com-
pared with PBS + RV-treated mice (Figure 5g). BAL MUC5AC
protein levels were also increased in elastase + RV- compared
with PBS + RV-treated mice at both time-points and compared
with elastase + UV-treated mice at day 1 post-challenge (Fig-
ure 5h). BAL MUC5B protein was increased in elastase + RV-
compared with PBS + RV-treated mice on day 4 post-challenge
(Figure 5i).
Assessment of lung function parameters in the single-dose
elastase model showed abnormalities consistent with human
COPD including increased FRC, TLC and increased dynamic
lung compliance associated with elastase administration (elastase
+ UV compared with PBS + UV-treated mice; Figures 6a–6c).
We did not observe any additional effect of RV infection on these
abnormal parameters at day 1 post-challenge with no increases
251c© 2015 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY) (http://creativecommons.
org/licenses/by/3.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
A. Singanayagam and others
252 c© 2015 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY) (http://creativecommons.
org/licenses/by/3.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
Mouse model of rhinovirus COPD exacerbation
in FRC, TLC or dynamic compliance observed in elastase + RV-
compared with elastase + UV-treated mice (Figures 6a–6c).
There were no significant effects of elastase treatment and/or
RV infection on tissue damping or lung hysteresis (Figures 6d
and 6e). We also assessed AHR measured as PenH using whole-
body plesmythography at 24 h post-RV challenge. Neither RV
infection nor elastase treatment alone caused increased AHR
compared with PBS + UV-treated controls. However, mice ex-
posed to single-dose elastase followed by RV infection had sig-
nificantly increased PenH at the highest dose of methacholine
compared with PBS + RV- or elastase + UV-treated mice
(Figure 6f).
In our humanmodel of RV-induced COPD exacerbation, there
was evidence of a deficiency in type I interferon responses to RV
[7]. We therefore assessed innate anti-viral immune responses
and virus loads in the single-dose elastase-induced COPDmodel.
Lung tissue IFN-λ levels were reduced in elastase + RV- com-
pared with PBS + RV-treated mice on day 1 post-infection (Fig-
ure 7a). There was no significant difference in lung IFN-β mRNA
levels (Figure 7b) and no significant effect of elastase treatment
on lung tissue RV RNA levels on either day 1 or day 4 post-
infection (Figure 7c).
DISCUSSION
Respiratory viral infections, especially with RVs, are associated
with a large proportion of COPD exacerbations [6,8], but under-
standing of the mechanisms by which viral infection enhances
disease is severely lacking. The development of mouse models
of COPD exacerbation, in parallel with the existing human ex-
perimental model [7], will allow insight into disease mechanisms
and testing of potential therapies. In the present study, we report a
newmousemodel of RV-induced COPD exacerbation. Ourmodel
is simple in comparison with the other existing animal model of
RV-induced COPD exacerbation [21], comprising just a single
intranasal administration of porcine pancreatic elastase, followed
by infection with minor group RV1B. We found that our model
mimics many of the key pathological features reported in human
experimental and naturally occurring disease, including enhanced
neutrophilic and lymphocytic airways inflammation, exaggerated
inflammatory cytokine production and increased airways mucus
production.
A variety of mouse models of COPD have previously been
described including various transgenic strains (e.g. overexpres-
sion of matrix metalloproteinase-1 [28] or IL-13 [29]) and ci-
garette smoke exposure [18]. Our base model of COPD com-
prises administration of porcine pancreatic elastase to induce
emphysematous lung damage. A criticism of this model is that it
does not employ the primary disease-causing agent unlike mod-
els based on cigarette smoke administration. However, smoke-
exposure models are acknowledged to be complex to set up,
require prolonged exposure and do not induce significant em-
physematous changes or lung function abnormalities consistent
with advanced disease. It is also notable that only 15–20% of
smokers develop COPD [30], thereby suggesting that cigarette
smoke exposure alone is insufficient to generate disease. Addi-
tionally, protease dysregulation can also cause COPD in humans
(in the case of patients with α-1 anti-trypsin deficiency), thereby
providing further rationale for use of elastase to induce features
of COPD in mice. Furthermore, acute exacerbations of disease
become more frequent as the disease progresses [31] and, there-
fore, elastase models may be more appropriate when studying
pathophysiological mechanisms involved in exacerbations. Some
previous studies have combined cigarette smoke exposure with
influenza or respiratory syncytial virus infection to model COPD
exacerbation in mice [32,33]. These studies have reported vari-
ous effects of cigarette smoke including increased [33] or reduced
[34] virus loads and enhanced [32,33] or suppressed [35] airway
inflammation. However, other disease-relevant parameters such
as mucus hypersecretion and lung function impairments have not
been assessed in thesemodels and, to date, no study has combined
cigarette smoke exposure with RV infection in mice.
Airway inflammation is known to be a key underlying patho-
logical process in COPD and neutrophilic inflammation is a re-
cognized characteristic of COPD in both stable-state and during
exacerbations [7,36,37]. In our initial efforts to try to reproduce
a published model [21] and then to try to optimize this model,
we found that multiple doses of elastase and LPS led to sup-
pression or no change rather than enhancement of RV-induced
airways neutrophilia and levels of inflammatory cytokines such
as TNF-α, CXCL10/IP-10, CCL5/RANTES and CXCL2/MIP-
2 compared with control PBS-dosed and RV-infected mice, the
equivalent of an RV-infected healthy control patient. This effect
on neutrophilia in particular could be due to the LPS compon-
ent of the model because a previous comparison showed atten-
uated BAL neutrophilia with chronic compared with acute LPS
challenge which was believed to be due to the resolution phase
of acute inflammation preventing further neutrophil recruitment
[38]. Additionally, a recent in vitro study demonstrated that LPS
administration attenuates RV-induced neutrophil chemokine ex-
pression [39]. More generally, the lack of enhancement of airway
inflammation is also in keeping with a previous study in which
a very high dose of elastase was administered to mice (12 units,
10-fold higher than in the present study) leading to severe lung
damage and impairment of subsequent inflammatory responses to
Streptococcus pneumoniae [19]. It was speculated that this could
Figure 5 RV infection enhances mucus production in a single-dose elastase COPD model
Mice were challenged intranasally with a single dose of elastase or PBS as control. Ten days later, mice were infected
intranasally with RV1B or UV-inactivated RV1B (UV). At day 4 after RV challenge, lungs were formalin-fixed, paraffin-embed-
ded and stained with PAS. Representative images of mice treated with (a) elastase + RV1B, (b) elastase + UV, (c) PBS
+ RV1B and (d) PBS + UV. Scale bars: 50 μm. Magnification ×400 (e) Scoring for PAS-positive mucus-producing cells.
(f) MUC5AC and (g) MUC5B mRNA in lung tissue was measured by Taqman quantitative PCR. (h) MUC5AC and (i) MUC5B
proteins were measured in BAL by ELISA. n=5 mice/group. Data were analysed by two-way ANOVA and Bonferroni post-hoc
test. *P< 0.05; **P< 0.01; ***P< 0.001.
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Figure 6 Single-dose elastase treatment induces lung function changes
Mice were challenged intranasally with a single dose of elastase or PBS as control. Ten days later, mice were infected
intranasally with RV1B or UV-inactivated RV1B (UV). At day 1 after RV challenge, forced manoeuvre techniques and
Flexivent were used to assess lung function parameters including (a) FRC, (b) TLC, (c) dynamic compliance, (d) tissue
damping and (e) lung hysteresis. (f) AHR was measured by whole-body plethysmography at day 1 post-infection. (a–e) n=10
mice/group, two independent experiments combined. Data analysis by one-way ANOVA and Bonferroni post-hoc test (f)
n=8 mice/group, two independent experiments combined. Data analysis by two-way ANOVA and Bonferroni post-hoc test.
*P< 0.05; **/ψψP< 0.01; ***P< 0.001. In (f), * indicates statistical comparison between elastase + RV and PBS +
RV groups and ψ indicates comparison between elastase + RV and elastase + UV groups.
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Figure 7 Deficient IFN-λ production in RV-infected mice with elastase-induced COPD
Mice were challenged intranasally with single-dose elastase or PBS as control. On day 10 after elastase or PBS challenge,
mice were additionally challenged intranasally with RV1B or UV-inactivated RV1B (UV). (a) IFN-λ mRNA, (b) IFN-β mRNA and
(c) RV RNA in lung tissue was measured by Taqman quantitative PCR. n=5 mice/group. Data were analysed by two-way
ANOVA and Bonferroni post-hoc test. ***P< 0.001.
be a consequence of airway epithelial damage or perhaps altered
alveolar macrophage function [19]. Therefore, given this finding
that severe lung damage can suppress the inflammatory response
to pathogens and the fact that chronic LPS challenge in itself also
causes emphysematous lung damage [38,40], it is perhaps not
surprising that chronic challenge with both of these agents led
to suppression of inflammatory responses to RV. In contrast, our
model of single-dose elastase led to significantly increased neut-
rophil numbers in theBALcomparedwith naivemicewith further
significant increases in neutrophilia at days 1 and 4 post-infection
when elastase was combined with RV infection compared with
either treatment alone. In addition to increased neutrophil num-
bers in elastase-treated mice infected with RV, we also observed
concomitant increased MPO activation, a protein that is released
from primary neutrophil granules following activation [41]. It is
known that neutrophil activation markers are increased in sputum
of patients with COPD compared with healthy controls [42,43]
and previous studies have also reported increased MPO activity
in sputum [13] or exhaled breath condensate [44] of patients with
COPD during exacerbations.
We also observed increased BAL lymphocytosis in mice re-
ceiving single-dose elastase followed by RV compared with con-
trol mice treated with PBS and RV or mice treated with elastase
and UV-inactivated virus. This finding is also in keeping with
our human model of COPD RV exacerbation where increased
lymphocytes in BAL were seen at 7 days after RV infection in
patients with COPD compared with healthy controls [7] with
a predominance of CD8+ T-cells [16]. Whether this represents
an appropriate or exaggerated response to RV infection and/or
contributes to lung parenchymal damage in COPD is unclear
[16]. Further consistent with human studies, we observed in-
creases in airway inflammatory cytokines in single-dose elast-
ase and RV-treated mice compared with either treatment alone,
including CXCL10/IP-10, CCL5/RANTES and TNF-α which
have all been shown to be up-regulated during naturally oc-
curring COPD exacerbations in comparison with stable state
[7,9,10,13,45].
Mucus hypersecretion and plugging of the airways is another
cardinal feature of COPD and increased MUC5AC and MUC5B
production has been demonstrated in histopathological specimens
from patients with COPD [46]. Furthermore, RV has been shown
to increase airway mucins in vitro [27,47] and in vivo [24,48],
and increased sputumproduction is a key symptomdescribed dur-
ing experimental exacerbations of disease [7]. In our model, we
found increases in lung tissue gene expression and BAL protein
levels of the major respiratory mucins MUC5AC and MUC5B in
mice treated with elastase followed by RV compared with con-
trol mice receiving PBS followed by RV. There is considerable
interest in selective therapeutic targeting of mucin production in
COPD and our mouse model provides an in vivo system that may
facilitate mechanistic dissection of the pathways involved to aid
development of therapeutic targets.
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Acute exacerbations of COPD are associated with increased
airway obstruction, which is believed to be secondary to in-
flammation and mucus hypersecretion [49]. In our human
model of disease, we observed significant reductions in post-
bronchodilator peak expiratory flow in patients with COPD infec-
ted with RV [7]. Assessment of airway resistance by whole-body
plethysmography in our single-dose elastasemousemodel did not
show any baseline differences between mice treated with elast-
ase compared with mice treated with PBS, but we did observe
increased AHR to methacholine challenge in mice exposed to
elastase and RV compared with treatment with elastase or infec-
tion with RV alone. AHR is considered to be a hallmark feature
of asthma, but is increasingly being recognized as a feature in
COPD [50]. However, it should be noted that the applicability of
non-invasive measurements of lung function such as whole-body
plesmythography may be questionable, as the technique does not
provide a direct assessment of lung mechanics and thus may not
be the optimum method for measuring lung function changes as-
sociated with chronic obstructive lung disorders such as COPD.
We therefore additionally used invasive techniques to directly
measure lung function in our model and found single-dose elast-
ase induced abnormalities consistent with human COPD includ-
ing increased TLC and FRC and increased pulmonary compli-
ance. Similar findings have been reported in previous studies
that have utilized single-dose elastase mouse models of COPD
[51,52]. In contrast with whole-body plethysmography, we did
not observe additional worsening of these parameters when RV
infection was combined with elastase treatment.
Our model of elastase-induced COPD did not, however, re-
create all features of human RV-induced COPD exacerbation that
have been reported. In our human model of experimental COPD
exacerbation we observed that deficient RV induction of IFN-β
in stable COPD ex vivo was followed by increased virus load fol-
lowing subsequent RV infection in vivo [7]. However, all of the
experimental protocols we assessed in mice, including single-
dose elastase and up to four doses of elastase and LPS, led to
similar or lower lung RV RNA levels compared with control PBS
+ RV-treated mice. These lower virus loads were accompanied
by the expected lower levels of IFN-β and IFN-λ in lung tis-
sues taken at the same time points in vivo. The lower virus loads
and accompanying lower levels in interferon induction in vivo
might, in part, be explained by the fact that the intranasal elast-
ase mouse model is associated with mucus hypersecretion in the
large airways (as shown by PAS-positive staining in the airway
lining). This may theoretically impair efficient binding of RV
to the bronchial epithelium and thereby lead to a reduction in
virus loads, as demonstrated by a previous study which repor-
ted reduced virus loads following influenza virus challenge in
MUC5AC-overexpressing mice [53]. We are unable to explain
the difference between our results in mice (lower virus loads ac-
companied by the expected lower levels of IFN-β and IFN-λ in
lung tissues taken at the same time points in vivo) and the find-
ings in the previous mouse model study employing four doses of
elastase and LPS [21] which reported the surprising findings of
greater virus loads accompanied by absent induction of IFN-α
and IFN-β in lung tissues taken at the same time point in vivo.
We also cannot explain the differences between our results re-
porting deficient RV induction of IFN-β in BAL cells from stable
COPD subjects ex vivo [7] and work from the same group in
air/liquid interface-cultured bronchial cells from patients with
moderate-to-severe COPD which demonstrated enhanced virus
replication but increased rather than decreased interferon induc-
tion at the same time points [54]. There may be subtleties in
design that can explain these apparently contradictory findings,
but relationships between interferon responses to RV infection
and virus replication in vitro and in vivo in COPD clearly re-
quire further study in both humans and mice. It is also notable
that, despite type I and III interferon responses being unchanged
or reduced in our single-dose elastase + RV model, BAL pro-
tein levels of the interferon-stimulated gene CXCL10/IP-10 were
actually enhanced. However, RV may induce certain interferon-
stimulated genes, independently of type I interferon signalling
[55], and other mediators such as TNF-α, which was enhanced
in our model, have been shown to up-regulate CXCL10/IP-10
in vitro [56]
In summary, we report a mouse model of RV infection in
COPD that mimics a number of inflammatory features of human
disease. This model, in conjunction with our human model, will
provide a useful tool for studying disease mechanisms and will
allow testing of novel therapies with potential to be translated
into clinical practice.
CLINICAL PERSPECTIVES
 RV infections commonly trigger exacerbations in patients with
COPD and are amajor cause ofmorbidity andmortality. There
is a lack of understanding of the underlying immunopatho-
logical mechanisms involved in virus-induced exacerbations
and no available effective therapies.
 The aim of the present study was to establish a mouse model
that reproduces the hallmark features of RV-induced exacer-
bation of COPD.
 A single elastase treatment followed by RV infection in mice
mimicked a number of hallmark inflammatory features of
human disease including enhanced cellular airways inflam-
mation, increased inflammatory cytokine expression and mu-
cus hypersecretion. This model will provide a useful tool for
studying disease mechanisms and allow future testing of novel
therapies with potential to be translated into clinical practice.
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